

Effective January 1, 2024

# Non-Preferred Part B Drug Request Form: Granix, Leukine, Neupogen, Nivestym, Releuko

If you would like to request a Non-Preferred Part B Drug, please complete this form and fax it to Elderplan's Pharmacy Department at 929-275-3223.

Member Information			
Member ID:			
Member Name:			
Date of Birth:			
Street Address:			
City/State/Zip:			
Member Phone #:			

Prescriber Information			
Prescriber Name:			
NPI #:			
Tax ID #:			
Address:			
City/State/Zip:			
Phone #:			
Fax #:			

Please consider the Preferred Drug for the member's treatment before proceeding to a drug that is on Elderplan's Non-Preferred Drug list.

	Colony Stimulating Factors – Short Acting		
Step 1 Drug (Preferred) <i>No Authorization Required</i>	• Zarxio (filgrastim-sndz)		
Step 2 Drugs	Granix (TBO-filgrastim)		
(Non-Preferred)	Leukine (sargramostim)		
Authorization Required	Neupogen (filgrastim)		
	Nivestym (filgrastim-aafi)		
	Releuko (filgrastim-ayow)		

Effective January 1, 2024



# **Non-Preferred Drug Exception Ouestions:**

#### Please answer ALL questions below.

- A. What is the name of the Step 2 (Non-Preferred) Drug that is being requested?
- B. What is the dosing regimen for the requested Non-Preferred Drug (specify drug name, drug strength, units per dose, frequency, days supply, and duration of therapy)?
- C. What is the ICD-10 code for the requested Non-Preferred Drug?
- D. What is the NDC of the requested Non-Preferred Drug?

## If request is for Neupogen, Nivestym, Granix, or Releuko:

i. Has the member received treatment with the requested Non-Preferred Drug in the past 365 days?

 $\Box$  Yes  $\Box$  No

ii. Does the member have a documented latex allergy and a latex-free product is necessary?

 $\Box$  Yes  $\Box$  No

iii. Is the requested dose for Neupogen, Nivestym, or Granix less than 180 mcg?

 $\Box$  Yes  $\Box$  No

iv. Has the member had a documented intolerable adverse event to the preferred drug, **Zarxio**, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the brand and biosimilar medications)?

 $\Box$  Yes  $\Box$  No


> Please explain below or attach supporting documentation:

### If request is for Leukine:

i. Has the member received treatment with the requested Non-Preferred Drug in the past 365 days?

 $\Box$  Yes  $\Box$  No

# **Elderplan Part B Drug Step Therapy Program**





ii. Is Leukine being requested for an indication that is not FDA-approved for the preferred drug, Zarxio?

 $\Box$  Yes  $\Box$  No

iii. Has the member had a documented inadequate response or an intolerable adverse event to the preferred drug, **Zarxio**?

 $\Box$  Yes  $\Box$  No

> Please explain below or attach supporting documentation:

Elderplan will review this initial request and provide our decision within our standard timeframe of 72 hours.

If waiting the 72 hours standard timeframe may jeopardize the life or health of the member and an expedited decision within 24 hours is medically necessary, please explain below.

	Prescri	iber's	Signature
--	---------	--------	-----------

Date

#### Please fax this form to 929-275-3223 (Elderplan Pharmacy Department) upon completion.

If you have any questions or concerns, contact us at 347-977-7419 or 718-921-8841, Monday through Friday from 9 AM to 5 PM. A copy of Elderplan's Part B Step Therapy Program Drug List is located on Elderplan's Provider Web Portal and our website at <u>https://www.elderplan.org/for-providers/</u>.

Thank you, Elderplan Pharmacy Department